TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06249607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: storytelling
Description: Storytelling android program: Subjects in group A or the storytelling group will be given headphones to listen to stories for 30 min (i.e., between 9 and 10 pm). While the subject listens to the story, a relative will present in a corner of the room to record when they fell asleep, the relative will present again in the room to record the time of falling asleep. The intervention will be done 7 nights a week for a period of 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness breathing
Description: android program: Individuals in group B are instructed to sit upright in a comfortable position with eyes closed, focus on diaphragm movements while breathing in a slow, deep, relaxed manner, and to nonjudgmentally acknowledge and accept unwanted thoughts, ideas or images and return attention to the diaphragmatic breathing. In this exercise, individuals are instructed to notice the physical sensations of breathing, both inhalations and exhalations, with a focus on the natural rate of respiration as opposed to forcibly controlling the breath. Duration: 5 minutes in duration per session, before sleep for 7 days a week for a total duration of 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom.

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep hygiene
Description: Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom.
Study: NCT06241885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group I
Description: Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
Study: NCT06376409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Hair Growth Supplement
Description: Hair growth supplement for women ages 18 - 44

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Balance Hair Growth Supplement
Description: Hair growth supplement for women ages 45 - 70

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Vegan Hair Growth Supplement
Description: Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet
Study: NCT05348863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK
Description: The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
Study: NCT06153459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Clamping at ~30 seconds
Description: Care team will wait to clamp the umbilical between 1-\<60 seconds after birth. 30 seconds is the ideal time of clamping.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Clamping at ~120 seconds
Description: Care team will wait to clamp the umbilical cord between 60-180 seconds after birth.120 seconds is the ideal time of clamping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: For infants who need their cord clamped before the target in the DCC-120 group. Care team may milk the umbilical cord towards the infant four times. Cord milking should NOT be performed if the delay meets or exceeds 60 seconds.~Umbilical cord milking will not be provided among participant-infant dyads in the DCC-30 group.
Study: NCT04966858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Caloric Refeeding (ICR)
Description: Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Calorie Refeeding (HCR)
Description: Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
Study: NCT05795634

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trier Social Stress Test
Description: Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
Study: NCT06401213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTX-463
Description: MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo-- Normal Saline
Study: NCT06234943

Intervention type: OTHER
Group type: OTHER
Intervention: Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results
Description: Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
Study: NCT03978793

Intervention type: DEVICE
Intervention: MyTPill, a digital pill
Description: MyTPill is a digital pill containing an approved medication
Study: NCT06347796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Conventional surgery is surgical drainage through burr holes or craniotomy.
Study: NCT06376409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Postpartum Hair Growth Supplement
Description: Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
Study: NCT06222762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Personalized follow-up in adapted physical activities
Study: NCT06347796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Middle Meningeal Artery Embolization (MMAE)
Description: Particle embolization of the middle meningeal artery with micron variants of the Embosphere Microspheres or CONTOUR Embolization Particles device.
Study: NCT06517108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chuna therapy
Description: The chuna therapy group will receive chuna therapy based on the degree of displacement of the lumbar, ilium, sacrum, and cervical vertebrae. The type of weight or treatment is selected based on the clinical judgment of the Korean medicine practitioner (HVLA: high-velocity low-amplitude thrust, drop table manipulation, muscle energy techniques, myofascial release, etc.). The area and number of treatments performed are recorded separately. Thermotherapy is applied as an adjuvant treatment.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: The physical therapy group will receive transcutaneous electrical nerve stimulation (TENS) for about 10 to 15 minutes, and the area and number of times it was administered will be recorded. Thermotherapy is applied as an adjuvant treatment, and the area and number of times it is applied are recorded separately.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement.
Study: NCT06456866

Intervention type: OTHER
Intervention: interpretation
Description: interpretation of blood gases samples

Intervention type: OTHER
Intervention: interpretation
Description: interpretation of blood gases samples
Study: NCT04670081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: 25 mg, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 5 mg, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 5 mg, p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide
Description: 100 mg, p.o.
Study: NCT04781673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Will receive titratable infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
Study: NCT04634435

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Description: Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2
Study: NCT06538038

Intervention type: DRUG
Intervention: Osimertinib
Description: Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.

Intervention type: DRUG
Intervention: Osimertinib + Chemotherapy
Description: Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
Study: NCT06083233

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: External lumbar drainage
Description: External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: External lumbar drainage
Description: External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
Study: NCT05185635

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
Study: NCT05340296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Youth Connect
Description: This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
Study: NCT06099925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy
Study: NCT05642104

Intervention type: DRUG
Intervention: Neoadjuvant therapy
Description: all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
Study: NCT05091788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Aime
Description: Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
Study: NCT05938790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Fetal Monitoring
Description: Fetal doppler used to monitor fetal heart rate in triage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care Handheld Ultrasound
Description: Point of Care Handheld Ultrasound
Study: NCT05412758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Stimulant Drink
Description: For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Stimulant Drink
Description: For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Stimulant Drink
Description: For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
Study: NCT06314321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
Study: NCT05585658

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin alpha
Description: To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin alpha
Description: To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
Study: NCT05411809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug adjuvant therapy
Description: The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
Study: NCT05683509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep collagen layer, xenograft and collagen membrane
Description: Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft and collagen membrane
Description: Alveolar ridge preservation is done using xenograft and collagen membrane only
Study: NCT04668339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 single dose priming
Description: ARCT-021 higher dose (one dose) + placebo (one dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 single dose priming
Description: ARCT-021 higher dose (one dose) + placebo (one dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 two lower dose priming
Description: ARCT-021 lower dose (two doses, Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 two lower dose priming
Description: ARCT-021 lower dose (two doses, Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 two higher dose priming
Description: ARCT-021 higher dose (two doses, Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021 two higher dose priming
Description: ARCT-021 higher dose (two doses, Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (two doses), priming
Description: Placebo (two doses, Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (two doses), priming
Description: Placebo (two doses, Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Randomized booster
Description: ARCT-021 (single dose) OR placebo, booster

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo booster
Description: Placebo (single dose)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo booster
Description: Placebo (single dose)